Overview

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

Status:
NOT_YET_RECRUITING
Trial end date:
2026-08-18
Target enrollment:
Participant gender:
Summary
The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.
Phase:
PHASE1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC